HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Penetration of parenterally administered rifampicin into bone tissue.

Abstract
This study in 32 patients was undertaken to determine the penetration of rifampicin into bone tissue using the recently developed intravenous formulation of this antibiotic. 300 mg rifampicin given as an intravenous injection over 5 min followed by 300 mg slow intravenous drip infusion over 1 h give a plasma level of rifampicin of more than 2 micrograms/ml for 6 h. In patients with osteomyelitis, bone rifampicin concentrations ranged from 1.4 to 8.8 micrograms/g at 2.5-3.5 h after the start of treatment. Osteomyelitis due to gram-positive organisms and to Haemophilus can be treated with rifampicin in combination with a second antibiotic, depending on the minimum inhibitory concentration of the infecting organism(s).
AuthorsB Roth
JournalChemotherapy (Chemotherapy) Vol. 30 Issue 6 Pg. 358-65 ( 1984) ISSN: 0009-3157 [Print] Switzerland
PMID6518835 (Publication Type: Journal Article)
Chemical References
  • Rifampin
Topics
  • Adult
  • Aged
  • Bone and Bones (metabolism)
  • Haemophilus Infections (drug therapy, metabolism)
  • Humans
  • Infusions, Parenteral
  • Kinetics
  • Middle Aged
  • Osteomyelitis (drug therapy, metabolism)
  • Rifampin (administration & dosage, metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: